Javelin gets Hospira loan and court date
This article was originally published in Scrip
Hospira has agreed to pay a $2 million loan to its acquisition target Javelin Pharmaceuticals on 10 June, after the latter launched a lawsuit claiming Hospira had breached the terms of their merger agreement. Under the agreement, Hospira was to pay Javelin up to $4 million in monthly instalments of up to $2 million each to cover working capital and general corporate purposes.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.